Merus to Present at the Jefferies 2018 London Healthcare Conference
UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer of Merus, will present a company overview at the Jefferies 2018 London Healthcare Conference on Thursday, November 15, 2018, at 3:20 p.m. GMT.
A live webcast of the presentation will be available on the Investors and Media page of the Company's website, http://www.merus.nl . A replay of the presentation will be archived and available on the Merus website site for a limited time following the event.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Additional pipeline programs include MCLA-117, which is currently being studied in a Phase 1 clinical trial in patients with acute myeloid leukemia, and MCLA-158, a Biclonics® being studied in a Phase 1 clinical trial in patients with solid tumors with an initial focus on metastatic colorectal cancer. Through its collaboration with Incyte Corporation, Merus is also developing a preclinical bispecific antibody designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. For additional information, please visit Merus’ website, www.merus.nl.
Investor and Media Inquiries:
Investor Relations and Corporate Communications
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Worksoft20.5.2019 17:56:04 CEST | Pressemeddelelse
Deutsche Telecom to Showcase How Intelligent Automation is Driving Quality and Program Efficiencies for ERP Transformation
Merus N.V.20.5.2019 14:41:11 CEST | Pressemeddelelse
Merus to Present at the RBC Capital Markets 2019 Healthcare Conference
Dolby Laboratories17.5.2019 14:32:30 CEST | Pressemeddelelse
First Dolby Cinema Opens in Germany with Kinopolis Gruppe in Munich
YPO17.5.2019 08:03:33 CEST | Pressemeddelelse
Four Progressive Leaders to Receive the 2019 YPO Global Innovation Awards
Dalhousie University16.5.2019 21:12:23 CEST | Pressemeddelelse
Dr. Deep Saini appointed as Dalhousie University’s 12th President
PureCircle16.5.2019 18:03:24 CEST | Pressemeddelelse
PureCircle and Merisant Renew Stevia Supply Agreement
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum